Sclerotherapy with 6% polidocanol solution in patients with placenta accreta
Objective: Placenta accreta is one of the main obstetrical complications worldwide. The aim of this study was to report the experience of managing placenta accreta with a 6% polidocanol solution sclerotherapy. Materials and Methods: We selected patients between 37 weeks of gestation and 38 weeks of...
Saved in:
Main Authors: | Ricardo Mauricio Malagón Reyes (Author), Rubén Castorena de Ávila (Author), María de Jesús Ángeles Vázquez (Author), César Augusto Núñez Monteagudo (Author), Hugo Mendieta Zerón (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2016-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Sclerotherapy for placenta accreta: Some concerns
by: Shigeki Matsubara, et al.
Published: (2017) -
Therapeutic Effect of Polidocanol Sclerotherapy on Oral Vascular Malformations
by: Satoshi Fukuzawa, et al.
Published: (2021) -
Successful Treatment of Acquired Vulvar Lymphangiectasia with 1% Polidocanol Sclerotherapy
by: Carolyn M. Stull, et al.
Published: (2021) -
The Efficacy of Polidocanol foam Sclerotherapy in Treatment of Infantile Hemangioma and Slow-Flow Vascular Malformation
by: Suhail Ibraheem Kadhum, et al.
Published: (2016) -
Effect of Hyaluronic Acid and Pluronic-F68 on the Surface Properties of Foam as a Delivery System for Polidocanol in Sclerotherapy
by: Teresa del Castillo-Santaella, et al.
Published: (2020)